In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...